Leronlimab, RANTES, COVID-19 (Coronavirus) Discussion with Dr. Bruce Patterson of IncellDX
Roundtable video conference regarding leronlimab and RANTES with Dr. Bruce Patterson of IncellDX.
Leronlimab is a humanized monoclonal IgG antibody that blocks CCR5. CCR5 receptor and RANTES complex then transduces a signal by increasing the intracellular calcium ion level and activating the enzymes GTPases.
Leronlimab was originally developed for HIV and works by blocking the CCR5 receptor and stopping the calcium signaling.
So by blocking the CCR5 receptor on leukocytes, the idea with leronlimab is you are blocking the transmission of the chemokine signal from RANTES, thus preventing the migration of more immune cells to attenuate a cytokine storm.
It is also believed that leronlimab’s other effect is polarization of macrophages from pro-inflammatory to antinflammatory phenotypes.
This roundtable discussion with Drs. Patterson, Hansen and Yogendra goes over recently updates regarding leronlimab, RANTES, new clinical trials and data and why leronlimab might be the game changer to treat sever COVID-19 infections.
